Literature DB >> 12583848

Sleep disturbances in Parkinson's disease.

Cynthia L Comella1.   

Abstract

Disorders of sleep and daytime alertness are frequent in Parkinson's disease patients and arise from a number of diverse factors. The most common complaint of night-time sleep disturbance in Parkinson's disease is sleep fragmentation. Sleep fragmentation can be associated with recurrent parkinsonian symptoms, the effect of medications, concomitant medical disorders such as nocturia, or psychiatric disorders such as depression or anxiety. Likewise, nocturnal sleep disturbance may arise from sleep apnea, periodic limb movements of sleep, or rapid eye movement (REM) sleep behavior disorder. Nocturnal sleep deprivation may lead to excessive daytime sleepiness. Other potential sources of daytime sleepiness include the effects of medications or disruption of central sleep mechanisms due to the pathologic processes of Parkinson's disease itself. Diagnosis of sleep disturbances and daytime sleepiness requires a direct interview of the patient and the caregiver, and may involve consultation with the sleep specialist or medical physician. Treatment is aimed toward improving night-time sleep and daytime drowsiness by addressing the causative factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583848     DOI: 10.1007/s11910-003-0073-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  63 in total

1.  Decreased striatal dopaminergic innervation in REM sleep behavior disorder.

Authors:  R L Albin; R A Koeppe; R D Chervin; F B Consens; K Wernette; K A Frey; M S Aldrich
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

Review 2.  Paradoxical sleep and its chemical/structural substrates in the brain.

Authors:  B E Jones
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  Magnetic resonance findings in REM sleep behavior disorder.

Authors:  A Culebras; J T Moore
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

4.  Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.

Authors:  R Pahwa; K Lyons; D McGuire; R Dubinsky; J P Hubble; W C Koller
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

5.  Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.

Authors:  J J Askenasy; M D Yahr
Journal:  Neurology       Date:  1985-04       Impact factor: 9.910

6.  Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

Authors:  I Arnulf; A M Bonnet; P Damier; B P Bejjani; D Seilhean; J P Derenne; Y Agid
Journal:  Neurology       Date:  2000-07-25       Impact factor: 9.910

7.  Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness.

Authors:  S Overeem; J J van Hilten; B Ripley; E Mignot; S Nishino; G J Lammers
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

8.  Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls.

Authors:  E K Tan; S Y Lum; S M C Fook-Chong; M L Teoh; Y Yih; L Tan; A Tan; M C Wong
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

9.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy.

Authors:  E C Hirsch; A M Graybiel; C Duyckaerts; F Javoy-Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

10.  Sleep disruption in Parkinson's disease. Assessment by continuous activity monitoring.

Authors:  B van Hilten; J I Hoff; H A Middelkoop; E A van der Velde; G A Kerkhof; A Wauquier; H A Kamphuisen; R A Roos
Journal:  Arch Neurol       Date:  1994-09
View more
  12 in total

1.  Sleep disorders and daytime sleepiness in Parkinson's disease.

Authors:  Renee Monderer; Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

Review 2.  Behavioral phenotyping of mouse models of Parkinson's disease.

Authors:  Tonya N Taylor; James G Greene; Gary W Miller
Journal:  Behav Brain Res       Date:  2010-03-06       Impact factor: 3.332

3.  The impact of sleep quality on cognitive functioning in Parkinson's disease.

Authors:  Karina Stavitsky; Sandy Neargarder; Yelena Bogdanova; Patrick McNamara; Alice Cronin-Golomb
Journal:  J Int Neuropsychol Soc       Date:  2011-12-09       Impact factor: 2.892

4.  Sleep quality in Parkinson disease: an examination of clinical variables.

Authors:  Karina Stavitsky; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2011-06       Impact factor: 1.600

Review 5.  Excessive daytime sleepiness in patients with Parkinson's disease.

Authors:  Bettina Knie; M Tanya Mitra; Kartik Logishetty; K Ray Chaudhuri
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

6.  Sleep in genetically confirmed pantothenate kinase-associated neurodegeneration: a video-polysomnographic study.

Authors:  Maria Livia Fantini; Giovanni Cossu; Andrea Molari; Monia Cabinio; Ozlem Uyanik; Roberto Cilia; Maurizio Melis; Angelo Antonini; Luigi Ferini-Strambi
Journal:  Parkinsons Dis       Date:  2010-06-29

7.  Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.

Authors:  Tonya N Taylor; W Michael Caudle; Kennie R Shepherd; AliReza Noorian; Chad R Jackson; P Michael Iuvone; David Weinshenker; James G Greene; Gary W Miller
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

8.  Dopamine-induced nonmotor symptoms of Parkinson's disease.

Authors:  Ariane Park; Mark Stacy
Journal:  Parkinsons Dis       Date:  2011-04-11

Review 9.  Psychiatric aspects of Parkinson's disease.

Authors:  Sandeep Grover; Mansi Somaiya; Santhosh Kumar; Ajit Avasthi
Journal:  J Neurosci Rural Pract       Date:  2015-01

10.  Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson's disease.

Authors:  Weidong Pan; Shin Kwak; Guoyan Li; Yiyun Chen; Dingfang Cai
Journal:  Chin Med       Date:  2013-07-27       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.